#USA #San Francisco #AI Inference #Benchling #Baseten

Introduction

In the rapidly evolving landscape of biotechnology, the integration of artificial intelligence has become a game-changer. The recent collaboration between Benchling and Baseten aims to reshape this sector by introducing Benchling Inference, a solution designed to boost the research and development capabilities of biotech companies through enhanced AI inference capabilities.

The Power of Benchling Inference

Benchling Inference equips biotech teams with scalable and economically viable GPU resources that enable them to efficiently train and deploy scientific models. This tool is particularly beneficial for biopharma companies, eliminating the complexities of infrastructure management. Moreover, it comes pre-loaded with many of today's leading scientific models and includes necessary integrations that facilitate in silico discovery right from the start.

With the surge in AI technological advancements observed between 2020 and 2025, the number of new AI models in scientific research skyrocketed from 28 to over 380. Despite the rapid growth of these models, there has been a significant lag in the computational resources available for their deployment. Traditional drug discovery processes are often characterized by bursts of data generation—scientists collect data in waves, requiring powerful computational resources to process extensive predictions in tight timeframes. Unfortunately, many computational science teams struggle with long backlogs, inefficient queues, and idle resources during quieter periods.

Benchling Inference is built on the solid foundation of the Baseten Inference Stack, renowned for its optimized performance. This stack mirrors the infrastructures of major cloud service providers and is designed for rapid operation, featuring cold start times between 5 to 10 seconds. Benchling enhances this base by overlaying biotech-specific defaults for deployment and operational options that satisfy strict data residency regulations—an essential requirement for many organizations.

Features and Flexibility

One of the standout features of Benchling Inference is its flexibility. Scientists can deploy third-party models or utilize their internally developed models, leveraging their experimental datasets within a unified computing environment. This capability is critical for teams dealing with sensitive data, as the Baseten Inference Stack operates seamlessly within various cloud environments, including private clouds, ensuring compliance with data sovereignty mandates.

Computational scientists working in Jupyter notebooks can now access inference capabilities directly through Benchling, thoroughly integrating AI into practical use cases in the lab. Amir Highighat, CTO and co-founder of Baseten, highlights the strategic importance of access to computing power, stating, "Biotech has entered a new era where AI models trained on proprietary experimental data could unlock breakthroughs that weren't possible before."

Addressing Challenges in Drug Discovery

The challenges faced by biotech companies, particularly when it comes to drug discovery, have been significant. Ashu Singhal, co-founder and president of Benchling, emphasizes how persistent issues surrounding inference implementation in drug discovery often hinder scientific progress. With workloads that can vary drastically and data often constrained by privacy concerns, resource costs become a critical barrier.

"We've been running Baseten internally for Benchling's Model Hub and learned a lot about tailoring inference for drug discovery. Now we want customers to have the same access," Singhal explains. This sentiment reflects the company’s dedicated approach to breaking down barriers in biotechnology research.

Conclusion

The partnership between Benchling and Baseten is poised to mark a significant milestone in the biotech sector. With Benchling Inference, companies can potentially revolutionize their research approaches, making AI-driven discovery not just a possibility, but a practical reality. For firms eager to stay ahead in this competitive landscape, integrating advanced AI capabilities into their workflows is no longer an option but a necessity. As Benchling continues to support over 1,300 companies worldwide, from emerging startups to industry giants, it is clear that the synergy created with Baseten will further accelerate breakthroughs in biotechnology, paving the way for faster innovations and impactful healthcare solutions.